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Abstract
Background: Sub-Saharan Africa cancer registries are beset by an increasing cancer burden further exacerbated by the AIDS
epidemic where there are limited capabilities for cancer-AIDS match co-registration. We undertook a pilot study based on a
‘‘strength-of-evidence’’ approach using clinical data that is abstracted at the time of cancer registration for purposes of
linking cancer diagnosis to AIDS diagnosis.
Methods/Findings: The standard Nairobi Cancer Registry form was modified for registrars to abstract the following clinical
data from medical records regarding HIV infection/AIDS in a hierarchal approach at time of cancer registration from highestto-lowest strength-of-evidence: 1) documentation of positive HIV serology; 2) antiretroviral drug prescription; 3) CD4+
lymphocyte count; and 4) WHO HIV clinical stage or immune suppression syndrome (ISS), which is Kenyan terminology for
AIDS. Between August 1 and October 31, 2011 a total of 1,200 cancer cases were registered. Of these, 171 cases (14.3%) met
clinical strength-of-evidence criteria for association with HIV infection/AIDS; 69% (118 cases were tumor types with known
HIV association – Kaposi’s sarcoma, cervical cancer, non-Hodgkin’s and Hodgkin’s lymphoma, and conjunctiva carcinoma)
and 31% (53) were consistent with non-AIDS defining cancers. Verifiable positive HIV serology was identified in 47 (27%)
cases for an absolute seroprevalence rate of 4% among the cancer registered cases with an upper boundary of 14% among
those meeting at least one of strength-of-evidence criteria.
Conclusions/Significance: This pilot demonstration of a hierarchal, clinical strength-of-evidence approach for cancer-AIDS
registration in Kenya establishes feasibility, is readily adaptable, pragmatic, and does not require additional resources for
critically under staffed cancer registries. Cancer is an emerging public health challenge, and African nations need to develop
well designed population-based studies in order to better define the impact and spectrum of malignant disease in the
backdrop of HIV infection.
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tuberculosis and malaria combined. [8] The World Health
Organization (WHO) projects that by 2020 there will be 16
million and by 2030, 27 million new cancer cases, 70% of these
will be in developing nations, and an excess of 1 million cases will
occur in sub-Saharan Africa. [7,9–12] The cancer burden in the
sub-Saharan Africa region will continue to be complicated by the
AIDS epidemic.
As of December 2009, it was estimated that 33.3 million people
were living in the world with HIV infection, there are 2.6 million

Introduction
The global burden of cancer is assuming the mantle as a
worldwide public health problem. Estimates are that by 2010
cancer became the world’s single leading cause of death. [1–4]
This is substantiated by an estimated 12.7 million new cases and
7.6 million deaths based on Globocan 2008, which contributed
13% of the global mortality burden. [1,2,5–7] This eclipsed the
total number of deaths attributable to HIV infection/AIDS,
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registrars to abstract the following clinical data regarding HIV
infection/AIDS in a hierarchal approach from the medical records
at time of cancer registration from highest-to-lowest strength-ofevidence: 1) documentation of positive or negative HIV serology
test [i.e., commonly employed rapid HIV serology tests in Kenya
include: HIV-1/2 3.0 Rapid Test SD, Bioline (London, UK); UniGoldTM RecombigenH, Trinity Biotech PLC (Wicklow, Ireland);
and DetermineH HIV-1/2 Rapid Test, Abbott Laboratories
(Abbott Park, IL, USA)]; 2) documentation of combination
antiretroviral therapy (cARV) and/or the precise regimen in the
medical record; 3) laboratory report of CD4+ lymphocyte counts
and, 4) documentation in the medical record of WHO clinical
staging (I through IV) of HIV disease and/or medical record
documentation of immune suppression syndrome also commonly
referred to as immunosuppression syndrome or ISS, which is the
acronym for AIDS in Kenya. The modified NCR form underwent
ethical committee review at the KEMRI for the pilot data
reporting period, and was approved for use. All aspects of cancer
disease registration and capturing of HIV/AIDS clinical data
strictly adhered to Kenyan national ethical guidelines. A second
attempt to capture additional HIV serology data was undertaken
after initial data review in October 2011. In this instance, NCR
registrars were referred to the Comprehensive Care Clinic, a
multidisciplinary treatment center for management of patients
with HIV infection/AIDS and the Department of Radiation
Oncology both located on the KNH campus.

newly infected persons, and there are 1.8 million deaths that are
attributable to HIV/AIDS. [13,14] More than 95% of those living
with HIV disease reside in developing countries, and of these twothirds (22.5 million) reside in sub-Saharan Africa. [13–15] In subSaharan Africa the adult HIV seroprevalence rate is on the order
of 5.2% [15].
In Kenya, a country with a population of nearly 41 million
people, there are limited published data on cancer burden and
essentially no data on the impact of HIV infection on the incidence
of AIDS-related neoplasms. [16] Nairobi is the 121st largest city in
the world; the 8th largest in sub-Saharan Africa; and Kenya has
the 3rd highest population of persons living with HIV infection or
AIDS (PLWA) in Africa trailing only South Africa and Nigeria.
[15–17] The Nairobi Cancer Registry (NCR), established in 2001,
is the longest serving population-based registry (,3 million
persons) in Kenya; is housed in the Pathology and Oncology
Research Unit, Centre for Clinical Research at the Kenya Medical
Research Institute (KEMRI) in Nairobi; and is a flagship activity
of the Non-Communicable Diseases Research Programme. The
registry captures tumor registration from 24 healthcare entities
[e.g., Kenyatta National Hospital (KNH) the essential national
referral center in Nairobi; mission hospitals, private hospitals, and
hospice; other healthcare organizations and clinics, private
physician offices, and other entities all of which are located in
Nairobi, Kenya.][18] Not unlike other tumor registries in subSaharan Africa reporting periods and tumor registration are often
interrupted due to a variety of reasons; and many nations either
have nascent tumor registries or no registries at all. [18] In Kenya,
the HIV seroprevalence rate has fallen from 14% in the mid-1990s
to 6.3% in 2009. [16] In 2009, it was estimated that 1.5 million
Kenyans were living with HIV/AIDS inclusive of 6.3% adults
aged 15 and up; there were 180,000 children (aged 0–14 years)
living with HIV; and there were 80,000 deaths estimated due to
AIDS. [16] The NCR has been unable to link HIV incidence data,
although HIV is a reportable disease in Kenya, to cancer
registration; there is no computerized capability for registration;
and the registry must expand regionally and nationally to provide
more meaningful data. Similar challenges with cancer and HIV
infection co-registration or matching are encountered in other subSaharan African nations as well. We undertook a pilot study based
on a ‘‘strength-of-evidence’’ approach using clinical data that is
abstracted at the time of cancer registration for purposes of linking
cancer diagnosis to HIV infection/AIDS diagnosis.

Statistical Considerations
Comparisons were made between those individuals classified
solely by clinical criteria and those who had positive HIV serology
(documented on a HIV serology report contained in the medical
record) using a number of characteristics, including strength-ofevidence criteria, patient demographics, and proportion with
tumors known to be associated with HIV infection. Rates between
the two groups were compared via Chi-square tests, while age was
compared with a t-test (a = 0.05).

Results
Case Ascertainment
From August 1 to October 31, 2011 a total of 1,200 cancer
cases were registered from 10 centers, and subjected to verification
for HIV/AIDS association. Of these, 171 cancer cases (14.3%)
met clinical strength-of-evidence criteria for association with HIV
infection or AIDS (Table 1). These cases were diagnosed between
January 2006 and July 2011; 123 cases (72%) were diagnosed in
2010 and 2011.

Case Ascertainment and Methods
Cancer Registration
The NCR is a population registry and uses the National Bureau
of Statistics to define the census population as the denominator for
calculating incidence rates. Anyone who has lived/worked in
Nairobi in the past 6 months is considered a resident. For this
preliminary study, cancer registration (there was no specified time
period for cancer diagnosis) was undertaken in a manner
consistent with KEMRI/NCR operating policies and procedures.
This includes scientific and ethical approval from the KEMRI
Scientific Steering Committee and Ethical Review Committee in
addition a letter from the Ministry of Health authorizing access to
medical records is also obtained. Given these procedures,
informed consent for tumor registration and data abstraction is
not obtained. All data was de-identified prior to analyses.

Strength-of-evidence of HIV/AIDS Association
Working from the hierarchal approach defined above, 25
(14.6%) of the 171 cases had definitive documentation of HIV
infection with laboratory reports confirming positive HIV
serology. Of the remaining 146 clinical cases, 74 (50.7%) had
documentation of combination antiretroviral therapy; 28 (19.2%)
had documentation of CD4+ lymphocytes counts #350 cells/mL
[any CD4+ count was documented in 41 (28.1%) with a range 21–
1007 cells/mL]; and all 146 cases without documentation of
positive HIV serology fulfilled some of criteria listed above and/or
documentation of immunosuppression syndrome including WHO
clinical stage in the medical record. Table 2 summarizes the
composite data of the strength-of-evidence criteria utilized on the
basis of positive HIV serology vs. other clinical criteria; it is noted
these criteria are not mutually exclusive.

HIV/AIDS Association and Case Ascertainment
The standard NCR cancer registration form (CanReg4 that is
being updated with CanReg 5) [19,20] was modified for tumor
PLOS ONE | www.plosone.org
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Cancer Diagnosis

Table 1. Nairobi Cancer Registry (NCR) – reporting entities
comprising this cancer population-based registry utilized for
this study number of cases that met strength-of-evidence
criteria for cancer-AIDS (HIV infection) match.

Reporting Healthcare Entity
in Nairobi

Nos. HIV Cases
Identified (%)

Aga Khan University Hospital

1 (,1%)

Avenue Hospital

3 (2%)

Cancer Care Kenya

5 (3%)

Private physician clinic(s)

1 (,1%)

Karen Hospital

6 (4%)

Kenyatta National Hospital

86 (50%)

Metropolitan Hospital

2 (1%)

St. Mary’s Hospital

25 (15%)

Nairobi Hospice

31 (18%)

Nairobi West Hospital

2 (1%)

Registry of Births and Deaths, Nairobi

9 (5%)

Total

171 (100%)

Primary tumor site(s) were identified per standard registry
reporting methodology for all 171 cases (Table 4). Histology
reports were verified in 142 (83%), cytology in 6 (3.5%), and the
clinical record in the remaining 23 (13.5%) cases respectively. Of
the 171 cases, 118 (69%) were tumor types with known association
with HIV infection including Kaposi’s sarcoma (n = 55), cervical
cancer (n = 42), non-Hodgkin’s lymphoma (n = 15), Hodgkin’s
disease (n = 4), and carcinoma of the conjunctiva (n = 2; out of 10
‘‘orbital tumors’’). There was a preponderance of female cases 112
(65%) and the median age at cancer diagnosis was 39 years (range
7–82). Two children were registered. An 8-year old boy with
Burkitt’s lymphoma meeting HIV clinical criteria; and another 7year old boy with Kaposi’s sarcoma and with documented HIV(+)
serology.

Discussion
The Kampala Cancer Registry, which is based in Kyadondo
County in Uganda, is among the oldest tumor registries in subSaharan Africa and has successfully conducted AIDS-cancer
match disease surveillance. [21,22] In Kenya and for much of subSaharan Africa, however, there is limited or no capability for
electronic or other linkage of cancer and AIDS cases for disease
co-registration. This study to our knowledge represents the first-ofits-kind, to pilot a cancer-AIDS match registration strategy based
on the merits of clinical strength-of-evidence. Clinical HIV
infection data was retrieved in a hierarchal manner upon review
of medical records documentation at time of cancer registration.
Documentation of positive HIV serology and/or plasma HIV-1
RNA viremia (i.e., viral load) provides unequivocal evidence (sine
qua non) of HIV infection. Using this as a departure point and
uncertain of how frequently these laboratory parameters would be
identified in the medical records at time of cancer registration, we
chose to develop in a pragmatic and teachable manner, other tiers
of evidence for tumor registrars. Drug prescription is frequently, if
not always, documented in Kenyan medical records given its
reliability since patients have to pay for all their medications or
secure medicines through specialty programs and clinics. We
chose this as the next tier of evidence. This then afforded the NCR
leadership staff and physicians an opportunity to readily train
registrars on the different antiretroviral agents and regimens
commonly prescribed for HIV infection in Kenya. [23,24] We
next selected other laboratory evidence of HIV infection and in
this instance restricted our review to documentation of CD4+

doi:10.1371/journal.pone.0085881.t001

Upon referral to two other treatment facilities per NCR policies
of the original 146 cases that fulfilled clinical criteria for evidence
of HIV infection and or AIDS, an additional 22 confirmed HIV(+)
serology cases were identified. This included 12 cases at the
Comprehensive Care Clinic and 10 cases at the Department of
Radiation Oncology both based at KNH. Data from these two
groups of HIV(+) serology cases were reported separately for
descriptive purposes, but were combined to compare to those 124
individuals that fulfilled clinical criteria for evidence of HIV
infection but did not have a known positive HIV serology. When
combined, the HIV(+) serology group [n = 47 (27%)] was not
found to be statistically significantly different from the clinical
criteria-only group [n = 124 (73%)] for most characteristics, except
for rate of those who had a specific cARV regimen [34% in the
HIV(+) group compared to 18% in the clinical criteria-only group
(see Table 2)] and for gender [51% male in the HIV(+) group
compared to 28% male in the clinical criteria-only group (see
Table 3)].

Table 2. Level of strength-of-evidence of HIV infection/AIDS in 171 cancer cases that were registered.

HIV Serology
Level Strength-of-Evidence

Total
(n = 171)

Initial HIV(+)
Serology (n = 25)

Subsequent Confirmed
HIV(+) Serology (n = 22)

Total HIV(+)
Serology

Clinical Criteria
Only (n = 24)

Any CD4+ lymphocyte count
CD4+ count ,350/mL

48 (28%)
30 (18%)

7 (28%)
2 (8%)

13 (37%)
8 (36%)

20 (33%)
10 (21%)

28 (23%)
20 (16%)

Any antiretroviral (cARV) therapy
Specific cARV regimen
Regimen not specified

87 (51%)
38 (22%)
49 (29%)

12 (48%)
3 (12%)
9 (36%)

16 (73%)
13 (59%)
3 (14%)

28 (60%)
16 (34%)
12 (26%)

59 (48%)
22 (18%)*
37 (30%)

WHO clinical stage and/or ISS
in medical record

171 (100%)

25 (100%)

22 (100%)

47 (100%)

124 (100%)

Of the subsequent confirmed HIV(+) serology 12 were identified at the Comprehensive Care Clinic and 10 at the Department of Radiation Oncology at Kenyatta National
Hospital. [Notes: *Statistically significant difference (p = 0.022) between positive serology group (n = 47) and clinical criteria only group (n = 124) with respect to the level
strength-of-evidence (Chi-square test)].
doi:10.1371/journal.pone.0085881.t002
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Table 3. Comparison of demographics and percentage with known HIV-associated cancer cases between those with HIV(+)
serology and those who met clinical criteria only.

HIV Serology
Patient Characteristics

Total
(n = 171)

Initial HIV(+)
Serology (n = 25)

Subsequent Confirmed
HIV(+) Serology (n = 22)

Total HIV(+)
Serology

Clinical Criteria Only
(n = 124)

Male sex

59 (35%)

14 (56%)

10 (45%)

24 (51%)

35 (28%)*

Median age (range) in years

39 (7–82)

41 (7–61)

39 (28–69)

40 (7–69)

39 (8–82)

Histological or cytological basis of
diagnosis (otherwise in clinical chart)

142 (83%)

19 (76%)

22 (100%)

41 (87%)

101 (81%)

Known HIV-associated tumor (i.e., KS,
cervix, NHL, conjunctiva, and HD)

118 (69%)

17 (68%)

18 (82%)

35 (74%)

83 (67%)

[Notes: *Statistically significant difference (p = 0.005) between positive serology group (n = 47) and clinical criteria only group (n = 124) with respect to the patient
characteristic (Chi-square test)].
doi:10.1371/journal.pone.0085881.t003

lymphocyte counts. We did not anticipate seeing any documentation of plasma HIV-1 RNA levels and this supposition was
indeed confirmed as there were no reports of HIV viral load
documented in the medical records. The paucity of laboratory
data is also explainable by the recognition that once an HIV
diagnosis is established in Nairobi, the bulk of patient care and
laboratory monitoring is done in highly specialized clinics. These
records are not part of the general medical records. Finally, any
historical comment that documented HIV infection by referencing
WHO clinical stage or presence of immune suppression syndrome
(ISS), which is frequently documented in medical histories, were
judged acceptable but was considered the lowest tier of evidence.

Knowledge for each of these hierarchal categories is readily
taught, comprehended, and implemented for disease registration
by cancer registrars.
With this backdrop it is important to recognize the spectrum of
malignancy that was identified in this pilot study. The 47 cases
with positive HIV serology are indicative of a verifiable 4% [47
HIV(+) cases/1,200 cancer cases)] HIV seroprevalence rate
among cancer cases registered and is reflective of the national
Kenyan HIV seroprevalence rate, which is on the order of 6.3%.
[15,16] Admittedly, risk of HIV infection is increased in cancer
patients given the high incidence of KS, cervical cancer, and NHL
in particular in Kenya and throughout sub-Saharan Africa. Thus,

Table 4. Tumor types of 171 cancer cases with hierarchal association of HIV infection/AIDS.

HIV Serology
Primary Tumor Type

Clinical Criteria
Only (n = 124)

Initial HIV(+)
Serology (n = 25)

Subsequent Confirmed
HIV(+) Serology (n = 22)

Total (n = 171)

Kaposi’s Sarcoma (KS)

37

6

12

55 (32%)

Cervix

31

5

6

42 (25%)

Non-Hodgkin’s lymphoma (NHL)

12

3

0

15 (9%)

Head and Neck

8

2

0

10 (6%)

Orbit/Conjunctiva

7/2

0

1/0

10 (6%)

Breast

5

4

0

9 (5%)

Stomach

3

1

0

4 (2%)

Hodgkin’s Disease (HD)

1

3

0

4 (2%)

NOS abdomen/carcinoma in situ NOS

3/1

0

0

4 (2%)

Skin (NOS)/Melanoma

2/0

0

0/1

3 (2%)

Uterus/Vulva

1/2

0

0

3 (2%)

Esophagus

2

0

0

2 (1%)

Colon

2

0

0

2 (1%)

Liver

1

0

1

2 (1%)

Kidney/Prostate

0/1

0

1/0

2 (1%)

Brain

0

1

0

1 (,1%)

Leukemia (NOS)

1

0

0

1 (,1%)

Lung

1

0

0

1 (,1%)

Pancreas

1

0

0

1 (,1%)

Of these total cases, 118 (69%) had demonstrable HIV association (i.e., KS, cervix, NHL, conjunctiva and Hodgkin’s disease) and the remaining 53 would be considered
non-AIDS-defining cancer. [Notes: Bold italics – known HIV-associated malignancy; NOS – not otherwise specified].
doi:10.1371/journal.pone.0085881.t004
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the 14% (171 clinical criteria cases/1,200 cancer cases) HIV
seroprevalance rate based on strength-of-evidence criteria is likely
within an acceptable boundary. Additionally, up to 69% (118) of
the 171 total cancer cases identified using our approach have
documented associations with HIV infection – KS, cervical
cancer, NHL, conjunctival carcinoma, and Hodgkin’s disease.
Of the 10 orbital tumors, only two were specifically diagnosed as
carcinoma of the conjunctiva, which is associated with HIV
infection and immunodeficiency. [25,26] It is plausible that these 8
other tumors are likely conjunctival in origin, and this would then
approximate 74% of cases with clearly established association with
HIV infection. Importantly, 87% of cancer cases had verifiable
histology or cytology reports that were confirmed in the medical
record, which is in keeping with international guidelines for cancer
registration.
The remaining 53 (31%) cancer cases (118 tumor types with
known HIV association of the 171 total cases) would be considered
to be non-AIDS-defining cancer with head and neck (10 cases),
breast (9), and orbital tumors (8) being the most frequently
encountered primary sites. Additionally, isolated cases of liver,
lung, and leukemia were identified and all have been reported in
the backdrop of HIV infection. These observations are entirely in
keeping with studies originating in the US and Europe since late
1990s to the mid-2000s on the declining incidence of HIV-related
tumors, such as KS and NHL in particular, and the increasing
burden of non-AIDS-defining cancer. [27–34] This is undoubtedly
attributed to aging of the HIV-infected population in the
developed world and the success of the contemporary cARV
therapeutic era in improving immune status and controlling viral
replication. Similarly, with roll out of international (e.g., US
PEPFAR program) and Kenyan national HIV treatment programs, similar dynamics of an aging HIV-infected patient
population and improved cARV coverage in Kenya and the rest
of the African continent, the emergence of non-AIDS-defining
cancers is likely just on the horizon. [5] In developed portions of
the world, strategies are already being implemented for screening
HIV-infected patients at increased risk for non-AIDS-defining
malignancy [35].

There are important limitations of our study. Among them is
the very small sample size derived over a 3-month period of time;
review of medical records that despite our hierarchal strength-ofevidence approach had limited documentation of HIV-serology;
other laboratory tests indicative of HIV infection were scant,
which precluded any correlation of immunodeficiency (level of
CD4+ count) with type of cancer diagnosis; and no documentation
of plasma HIV-1 RNA levels. For the most part the 47 cases that
were confirmed HIV(+) versus the clinical criteria only group
(n = 124) were fairly comparable. The only statistically significant
difference in the characteristics we analyzed were predominance of
male sex and precise documentation of cARV regimen in the
HIV(+) versus the clinical-criteria only groups. These differences
are not clinically significant and can be readily explained on the
basis that up to 25% of the HIV(+) group, the largest proportion,
were derived from the records of the KNH Comprehensive Care
Clinic. This clinic is a comprehensive HIV/AIDS treatment
center in Nairobi.
In summary, this pilot demonstration of a hierarchal, clinical
strength-of-evidence approach for cancer-AIDS registration in
Kenya establishes feasibility, is readily adaptable, pragmatic, and
does not require additional resources for critically under-staffed
cancer registries. Cancer is an emerging public health challenge in
Africa, and African nations need to develop well designed
population-based studies in order to better define the impact
and spectrum of malignant disease in the backdrop of HIV
infection and AIDS. [36,37] As we approach the midpoint of the
fourth decade of the AIDS pandemic, the emergence of nonAIDS-defining cancer in HIV-infected individuals, nearly a third
of cases based on this survey in Nairobi, is likely to evolve in Africa
as it did around the turn of the century in the developed world.
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